Autoimmune treatment review to bring before any BPC-157 conversation

Your diagnosis today

Immune and anti-inflammatory medicines you take now

Include biologics, steroids, NSAIDs and anything injected or infused.

What FDA's July 2026 review found

• BPC-157 was nominated for ulcerative colitis, Crohn's disease, celiac disease and tendonitis; FDA found no clinical studies of it in Crohn's disease, celiac disease or tendonitis.[1]
• The single ulcerative colitis trial FDA found was reported only as a meeting abstract, which FDA judged inadequate to support efficacy or safety.[1]
• FDA says injected or nasal BPC-157 may pose a significant risk of an immune reaction against the product.[1]
• Several FDA-approved medicines treat ulcerative colitis, which FDA describes as a serious chronic disease.[1]
• In its briefing for the July 23-24, 2026 advisory committee, FDA proposed not adding BPC-157 to the 503A bulks list, and said it would not make a final determination until the committee's input had been considered.[1]

Questions for your rheumatologist, gastroenterologist or neurologist

1. How active is my disease right now, and which test results would show it changing?
2. Would adding something new make it harder to tell whether a change is a flare?
3. Do my current immune medicines raise any concern about an unapproved injected peptide?
4. Which treatments with trial evidence for my diagnosis have I not yet tried?
5. If I had a reaction, how would we tell it apart from my disease?

Bring to the appointment

• Every medicine and supplement, with how you actually take it
• Recent blood tests and disease-activity scores
• Dates of recent flares and infections
• The full label of any peptide product you already have